Abstract:Background: Clinical evidence suggests that Esketamine (ESK) is an effective treatment for depression. However, the effects of Esketamine in treating depression-like behavior induced by neuropathic pain is unclear. The underlying molecular mechanisms require further investigation to provide new therapeutic targets for the treatment of clinical neuropathic pain-related depression. Methods: A neuropathic pain-related depression model was established in rats with spared nerve injury (SNI). Male Sprague-Dawley rats were randomly divided into four groups: Sham Group, SNI group, SNI + Normal Saline (NS) Group and SNI + ESK5mg/kg Group. Mechanical pain thresholds were measured to assess pain sensitivity in SNI rats. On the 14th day after surgery a forced swim test and sucrose preference test were used to evaluate the depressive-like behavior of rats in each group. Further, a proteomic analysis was used to quantify differentially expressed proteins. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were analyzed to explore the main protein targets of SNI in the medial prefrontal cortex. The expression of proteins was detected by Western blotting. Results: A neuropathic pain-related depression model was established. Compared with the Sham group, the mechanical pain threshold was decreased significantly (13.2 ± 1.0 vs. 0.7 ± 0.01 g n = 8), while immobility on the forced swim test was also decreased (93.1 ± 7.4 vs. 169.5 ± 9.6 s n = 8), and sucrose preference rate was significantly increased (98.8 ± 0.3 vs. 73.1 ± 1.4n = 7) in SNI group rats. Compared with the SNI + NS group, the mechanical pain threshold was not statistically significant, while immobility on the forced swim test was clearly decreased (161.1 ± 11.6 vs. 77.9 ± 5.0 s n = 8), and sucrose preference rate was significantly increased (53.1 ± 8.9 vs. 96.1 ± 1.4n = 7) in SNI + ESK5mg/kg group rats. To further investigate the underlying mechanism, we employed proteomics to identify proteins exhibiting more than a 1.2-fold difference (P < 0.05) in expression levels within each group for subsequent analysis. Relative to the Sham group, 88 downregulated and 104 up-regulated proteins were identified in the SNI group, while 120 and 84 proteins were up- and down-regulated in the Esketamine treatment group compared with the SNI + NS group. Compared with Sham group, the expressions of mGluR5 and Homer1a were up-regulated in the medial prefrontal cortex (mPFC) in SNI group (mGluR5:0.97 ± 0.05 vs 1.47 ± 0.15, Homer1a:1.03 ± 0.06 vs 1.46 ± 0.16n = 6), and down-regulated after intervention with Esketamine (mGluR5:1.54 ± 0.11 vs 1.06 ± 0.07, Homer1a:1.51 ± 0.13 vs 1.12 ± 0.34n = 6). Conclusions: Low-dose Esketamine appeared to relieve depression-like behavior induced by neuropathic pain. The Homer1a-mGluR5 signaling pathway might be the mechanism of antidepressant effect of Esketamine.

Ketamine Differentially Restores Diverse Alterations of Neuroligins in Brain Regions in a Rat Model of Neuropathic Pain-Induced Depression

Alterations in the Inflammatory Cytokines and Brain-Derived Neurotrophic Factor Contribute to Depression-Like Phenotype after Spared Nerve Injury: Improvement by Ketamine

Cortical Functional Hyperconnectivity in a Mouse Model of Depression and Selective Network Effects of Ketamine

Acute Single Dose of Ketamine Relieves Mechanical Allodynia and Consequent Depression-Like Behaviors in a Rat Model

Subanesthetic Dose of Ketamine Improved CFA-induced Inflammatory Pain and Depression-like Behaviors Via Caveolin-1 in Mice

Acute Ketamine Administration Attenuates Lipopolysaccharide-Induced Depressive-Like Behavior by Reversing Abnormal Regional Homogeneity in the Nucleus Accumbens

Contribution of DNA methyltransferases to spared nerve injury induced depression partially through epigenetically repressing Bdnf in hippocampus: Reversal by ketamine

Downregulation of Neuregulin 1-ErbB4 Signaling in Parvalbumin Interneurons in the Rat Brain May Contribute to the Antidepressant Properties of Ketamine

Ketamine reduces aversion in rodent pain models by suppressing hyperactivity of the anterior cingulate cortex

Ketamine Exerts Its Sustained Antidepressant Effects Via Cell-Type-specific Regulation of Kcnq2.

Role of ketamine-mediated-decreased expression of neuroligin-1 in the hippocampus on rats with post-traumatic stress disorder

Ketamine Contributes to the Alteration of Ca2+ Transient Evoked by Behavioral Tests in the Prelimbic Area of Mpfc: A Study on Chronic CORT-induced Depressive Mice

Loss of Phenotype of Parvalbumin Interneurons in Rat Prefrontal Cortex is Involved in Antidepressant- and Propsychotic-Like Behaviors Following Acute and Repeated Ketamine Administration

Low-Dose Ketamine Improves LPS-Induced Depression-like Behavior in Rats by Activating Cholinergic Anti-inflammatory Pathways

Regulation of glutamate transporter 1 via BDNF-TrkB signaling plays a role in the anti-apoptotic and antidepressant effects of ketamine in chronic unpredictable stress model of depression

Planar cell polarity proteins mediate ketamine-induced restoration of glutamatergic synapses in prefrontal cortical neurons in a mouse model for chronic stress

Inhibition of the l-arginine–nitric oxide pathway mediates the antidepressant effects of ketamine in rats in the forced swimming test

Ketamine and its metabolite, (2R,6R)-HNK, restore hippocampal LTP and long-term spatial memory in the Wistar-Kyoto rat model of depression

The effect and mechanism of low-dose esketamine in neuropathic pain-related depression-like behavior in rats

Ketamine-induced Antidepressant Effects Are Associated with AMPA Receptors-Mediated Upregulation of Mtor and BDNF in Rat Hippocampus and Prefrontal Cortex.

Pain mediates the improvement of social functions of repeated intravenous ketamine in patients with unipolar and bipolar depression